IDH1 and central nervous system cancer: The high incidence of glioma-specific IDH1 mutations has implicated them as an early event that occurs during gliomagenesis and provides utility in distinguishing low grade astrocytomas and oligodendrogliomas, as well as secondary glioblastomas from reactive gliosis and primary glioblastomas [3].